Remodulin should be used with caution in
patients with hepatic or renal impairment.

borowski coping

----

Expanded Labeling Increases Therapy Applications;
Allows Medication Delivery Using Subcutaneous,
Intravenous and Intrathecal (spinal ) Infusion

The diabetes business unit of Medtronic, Inc.
(www.
United Therapeutics is a biotechnology company focused on the
development and commercialization of unique products for patients with
chronic and life-threatening cardiovascular, cancer and infectious
diseases. In clinical trials, the most common
side effects reported with subcutaneous Remodulin therapy included
infusion site pain (85%) and infusion site reaction (83%).
There is no cost to participate in the study ."
About Amarin Corporation
Amarin Corporation plc is a neuroscience company focused on the
development and commercialization of novel drugs for the treatment of central
nervous system disorders.

dionne soign

sufferer coping

"Medtronic's proven skill in delivering difficult-to-administer drugs
is particularly well-suited for biotech proteins and peptides that
cannot be taken orally," said Robert Guezuraga , president of Medtronic
Diabetes.D.

Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's Annual Report on
Form 10-K for the year ended April 30, 2004.

rash rheumatologist

In addition to subcutaneous delivery, the infusion pump
is now cleared to deliver medications labeled for intravenous and
intrathecal (spinal) infusion.medtronic. This will be followed by
another 6 month observation phase in which all participants will receive
Miraxion. Miraxion , Amarin's lead development compound, is in
phase III development for Huntington's disease and in phase II development
for treatment-unresponsive depression.com.

peeks kc

com), headquartered in Minneapolis, is the world's
leading medical technology company, providing lifelong solutions for
people with chronic disease. Actual results may differ
materially from anticipated results.

Amarin Announces Commencement of Recruitment by Huntington Study Group for Miraxion Phase III Clinical Trial in Huntington's Disease

Miraxion is thought to stabilize nerve cell membranes and improve
neurological functioning, although the exact mechanism of action is not
currently known. Individuals
with mild to moderate Huntington's disease who are interested in
participating in this study should visit the Huntington's Study Group website
at: http://www.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties which may
cause the Company's actual results in future periods to be materially
different from any performance suggested herein.S.

kc musculoskeletal

Remodulin is an FDA approved drug as a continuous subcutaneous
infusion or intravenous infusion (for those not able to tolerate a
subcutaneous infusion) for the treatment of pulmonary arterial
hypertension in patients with NYHA Class II-IV symptoms to diminish
symptoms associated with exercise. The
Company assumes no obligation to update information on its expectations.

soign loonie

The HSG is a worldwide, not-for-profit group of
physicians and other clinical researchers who are experienced in the care of
Huntington's disease patients and dedicated to clinical research in
Huntington's disease.

monicas misconceptions

amarincorp.

kc lupus

While there are medications to help relieve
some of the disease symptoms, there is no known treatment to slow the
progression of Huntington's disease, which affects about 30,000 people in
North America.

peeks battling

LONDON, Amarin Corporation plc (NASDAQ:
AMRN) today announced that the Huntington Study Group ("HSG") has commenced
recruitment for the U. Participants will be
followed as "out-patients" at regular intervals for 12 months. For more information, please
refer to Amarin Corporation's Annual Report for 2004 on Form 20-F and its
Form 6-Ks as filed with the U.

borowski terri

"We are delighted
to offer a new therapy option to patients who struggle with pulmonary
arterial hypertension, an extremely devastating disease that
constricts the arteries serving the lungs, slowly causing heart
failure," said Martine Rothblatt, Ph. The company's products
include external insulin pumps, related disposable products, and a
continuous glucose monitoring system. Medtronic, Inc.S .

systemic musculoskeletal

S.
This current trial is designed to determine the effect of this daily dose of
Miraxion on motor (movement) signs and symptoms of Huntington's disease.
The current 12 month study includes a 6 month placebo controlled phase
with research subjects being randomly assigned to receive either Miraxion (2
grams total daily dose) or a matching placebo. Securities and Exchange Commission.

rheumatologist progression

Business Editors/Health/Medical Writers

NORTHRIDGE, Calif.
Similar to Medtronic's external insulin pumps used to treat
diabetes, the Model 407C general medication pump is a pager-size
device that delivers precise doses of medication to a patient's body.

connective systemic

Phase III clinical trial of Miraxion (TM) in
Huntington's disease.
Huntington's disease is an inherited disease of the brain that usually
begins between the ages of 30 to 50, and includes motor, cognitive and
behavioral signs and symptoms.
For press releases and other corporate information, visit our website at
http: //www.

systemic autoimmune

terri musculoskeletal

"
The external pump can deliver medications to treat a variety of
medical conditions including , but not limited to, cancer and pain.org or call the toll free number
+1-(800)-487-7671.

borowski sufferer

Among patients (n=38)
treated for twelve weeks with intravenous Remodulin in an open-label
study, two patients experienced either line infections or sepsis.
Other events potentially related to intravenous dosing of Remodulin
include arm swelling, paresthesias, hematoma and pain.

Huntington-Study-Group .

soign autoimmune

Rick Stewart, chief executive officer of Amarin, commented: "Commencement
of recruitment to the Phase III clinical trial for Miraxion is a major
milestone for Amarin.

lupus systemic

coping dionne

Food and Drug Administration (FDA) clearance of
expanded labeling for its external model 407C general medication
infusion pump .

rash coping

Medtronic Announces Expanded Labeling for Its Model 407C General Medication Pump

The new labeling allows Remodulin to be administered to patients
intravenously, in addition to subcutaneous delivery . Remodulin has not been
studied in conjunction with Flolan(R) or Tracleer(R).
The HSG will be conducting a clinical study (TREND-HD) of ultra-pure
ethyl-EPA in persons 35 years of age or older who have mild to moderate
Huntington's disease. Researchers at 43 sites in the United States and Canada will each
enroll approximately 7-8 research subjects with early signs of Huntington's
disease who are independently ambulatory (walking) and fully self sufficient
in activities of daily living , such as eating, dressing and bathing.

Lupus:Personal Pages consolidates and shares lupus patients personal websites.

Many patients offer peeks in their journals, share their progression and treatments, discuss coping strategies and their experiences while battling lupus.

misconceptions systemic

"
Medtronic MiniMed (www.com) is the world leader in pump
therapy and continuous glucose monitoring. Other
adverse events included headache (27%), diarrhea (25%), nausea (22%),
rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%),
edema (9%), pruritus (8%) and hypotension (4%). An earlier trial in subjects with Huntington 's disease
indicated that Miraxion at 2 grams daily was well tolerated over 12 months.

systemic peeks

(NYSE:MDT) today
announced U., chairman and chief executive
officer of United Therapeutics.minimed. Remodulin is a
potent pulmonary and systemic vasodilator and should be used only by
clinicians experienced in the diagnosis and treatment of pulmonary
arterial hypertension. Such risks and uncertainties
include , without limitation, the inherent uncertainty of pharmaceutical
research, product development and commercialization, the impact of
competitive products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports.

systemic pamphlets

"The expanded labeling allows us to explore new therapy
opportunities to help more patients who struggle with severe chronic
medical conditions.
Currently , Medtronic's general medication pump is being used to
deliver Remodulin(R), manufactured by United Therapeutics Corporation
(NASDAQ:UTHR), for the treatment of pulmonary arterial hypertension. "Since there is no known cure, this is
an important milestone for up to 50,000 Americans who suffer from this
difficult disease. An immense amount of energy and dedication has been
expended by all involved to achieve this significant objective.